This  original article published in the New England Journal of Medicine  reports the findings of the ASSET-IT trial, a phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial. This study investigates the efficacy and safety of early tirofiban infusion after standard intravenous thrombolysis for patients experiencing acute ischemic noncardioembolic stroke. The trial's primary outcome demonstrates that early administration of tirofiban significantly increases the likelihood of an excellent functional outcome at 90 days compared to placebo. However, the study also notes a slightly higher risk of symptomatic intracranial hemorrhage in the tirofiban group. The conclusions suggest that tirofiban may be a beneficial adjunct therapy for this specific patient population, though the generalizability is limited as the trial was conducted solely in China and excluded patients eligible for thrombectomy.